Clearsign Technologies Corporation Provides Full Year 2024 Update
| ClearSign Technologies Corporation Consolidated Balance Sheets
|
||||||
| (in thousands, except share and per share data) |
|
December 31, |
||||
| |
|
2024 |
|
2023 |
||
| ASSETS |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| Current Assets: |
|
|
|
|
|
|
| Cash and cash equivalents |
|
$ |
14,035 |
|
$ |
5,684 |
| Accounts receivable |
|
|
165 |
|
|
287 |
| Contract assets |
|
|
194 |
|
|
188 |
| Prepaid expenses and other assets |
|
|
454 |
|
|
350 |
| Total current assets |
|
|
14,848 |
|
|
6,509 |
| |
|
|
|
|
|
|
| Fixed assets, net |
|
|
238 |
|
|
275 |
| Patents and other intangible assets, net |
|
|
830 |
|
|
836 |
| Total Assets |
|
$ |
15,916 |
|
$ |
7,620 |
| |
|
|
|
|
|
|
| LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| Current Liabilities: |
|
|
|
|
|
|
| Accounts payable and accrued liabilities |
|
$ |
1,220 |
|
$ |
366 |
| Current portion of lease liabilities |
|
|
75 |
|
|
71 |
| Accrued compensation and related taxes |
|
|
671 |
|
|
703 |
| Contract liabilities |
|
|
73 |
|
|
1,116 |
| Total current liabilities |
|
|
2,039 |
|
|
2,256 |
| Long Term Liabilities: |
|
|
|
|
|
|
| Long term lease liabilities |
|
|
113 |
|
|
172 |
| Total liabilities |
|
|
2,152 |
|
|
2,428 |
| |
|
|
|
|
|
|
| Commitments and contingencies (Note 11) |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| Stockholders' Equity: |
|
|
|
|
|
|
| Preferred stock, $0.0001 par value, 2,000,000 shares authorized, no shares issued or outstanding |
|
|
- |
|
|
- |
| Common stock, $0.0001 par value, 87,500,000 shares authorized, 50,285,509 and 38,687,061 shares issued and outstanding |
|
|
5 |
|
|
4 |
| Additional paid-in capital |
|
|
112,796 |
|
|
98,922 |
| Accumulated other comprehensive loss |
|
|
(21) |
|
|
(17) |
| Accumulated deficit |
|
|
(99,016) |
|
|
(93,717) |
| Total stockholders' equity |
|
|
13,764 |
|
|
5,192 |
| |
|
|
|
|
|
|
| Total Liabilities and Stockholders' Equity |
|
$ |
15,916 |
|
$ |
7,620 |
| |
||||||
| The accompanying notes are an integral part of these consolidated financial statements. |
| ClearSign Technologies Corporation Consolidated Statements of Operations and Comprehensive Loss
|
||||||
| |
|
|
|
|
|
|
| (in thousands, except share and per share data) |
|
For the Year Ended |
||||
| |
|
December 31, |
||||
| |
|
2024 |
|
2023 |
||
| |
|
|
|
|
|
|
| Revenues |
|
$ |
3,596 |
|
$ |
2,403 |
| Cost of goods sold |
|
|
2,478 |
|
|
1,586 |
| Gross profit |
|
|
1,118 |
|
|
817 |
| |
|
|
|
|
|
|
| Operating expenses: |
|
|
|
|
|
|
| Research and development |
|
|
1,471 |
|
|
739 |
| General and administrative |
|
|
6,135 |
|
|
6,059 |
| Total operating expenses |
|
|
7,606 |
|
|
6,798 |
| |
|
|
|
|
|
|
| Loss from operations |
|
|
(6,488) |
|
|
(5,981) |
| |
|
|
|
|
|
|
| Other income, net: |
|
|
|
|
|
|
| Interest income |
|
|
516 |
|
|
324 |
| Government assistance |
|
|
664 |
|
|
255 |
| Other income, net |
|
|
9 |
|
|
208 |
| Total other income, net |
|
|
1,189 |
|
|
787 |
| Net loss |
|
$ |
(5,299) |
|
$ |
(5,194) |
| |
|
|
|
|
|
|
| Net loss per share - basic and fully diluted |
|
$ |
(0.11) |
|
$ |
(0.13) |
| |
|
|
|
|
|
|
| Weighted average number of shares outstanding - basic and fully diluted |
|
|
48,935,988 |
|
|
38,500,933 |
| |
|
|
|
|
|
|
| Comprehensive loss: |
|
|
|
|
|
|
| Net loss |
|
$ |
(5,299) |
|
$ |
(5,194) |
| Foreign-exchange translation adjustments |
|
|
(4) |
|
|
(9) |
| Comprehensive loss |
|
$ |
(5,303) |
|
$ |
(5,203) |
| |
||||||
| The accompanying notes are an integral part of these consolidated financial statements. |
SOURCE ClearSign Technologies Corporation
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment